Search Results
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
n=9: CS2009 was dosed at 20 or 30 mg/kg, Q3W plus docetaxel;(3) Group 3 (1L NSCLC monotherapy ), n=23: CS2009 was dosed at 20 or 30 mg/kg, Q3W;(4) Group 4 (1L squamous NSCLC combination therapy), n=19: CS2009 was dosed at 20 or 30 mg/kg Q3W plus paclitaxel/carboplatin, followed by CS2009
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
regimen plus chemotherapy as first-line treatment for PD-L1 negative or low-expressing NSCLC demonstrated encouraging efficacy signal and a favorable safety profile. The second stage of this PoC study—a randomized controlled trial of IBI363 3→1.5 mg/kg plus chemotherapy versus pembrolizumab plus chemotherapy
More news about: Innovent Biologics
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
patients and serious TRAEs in 2.3% of patients. No TRAEs led to elisrasib discontinuation, and no dose reductions were required.Elisrasib plus Pembrolizumab as First-Line Combination Therapy for Patients with KRAS G12C Mutation–Positive NSCLCFifty-two patients with previously untreated
More news about: D3 Bio
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
inherently limited, this result compares favorably with historically reported PFS outcomes for standard-of-care pembrolizumab monotherapy and pembrolizumab plus chemotherapy. In addition, an 83% response rate was observed in the high CPS (>20) subgroup (n=6), while a 67% response rate was also observed in
More news about: TiumBio
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
months:34% reduction in the risk of death - ivonescimab plus chemotherapy significantly prolonged OSIn the intent-to-treat (ITT) population, ivonescimab plus chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy (HR=0.66 [95% CI: 0.50–0.87], P=0.0017(＜0.0049).
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
(BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2025;36:S1707.7 Fayette J, et al. INTERLINK-1: A Phase III, randomized, placebo-controlled study of monalizumab plus cetuximab
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
months, apalutamide plus hormone therapy met both primary endpoints. The rate of pCR/MRD was 8.9 percent with apalutamide plus hormone therapy versus 1.0 percent with hormone therapy alone (odds ratio [OR], 10.17; 95 percent confidence interval [CI], 5.27-19.64; p<0.0001). Apalutamide plus hormone therapy
More news about: Johnson & Johnson
May 31, 2026, 05:30 ET MARSTEK dévoile la nouvelle gamme VENUS et fait entrer les batteries plug-in dans une nouvelle ère du stockage d'énergie résidentiel
domestique plus intelligente.VENUS E MAX — Première batterie plug-in tout-en-un de 10 kWh au mondeVENUS E MAX est destinée aux foyers ayant des besoins énergétiques plus importants et des installations photovoltaïques existantes, offrant une solution de stockage plus puissante et
More news about: Marstek Energy Co., Limited
May 31, 2026, 05:13 ET Zendure et Sunergy s'associent pour accélérer la gestion intelligente de l'énergie résidentielle aux Pays-Bas
résidentielle. Alors que le marché néerlandais de l'énergie s'oriente vers une utilisation plus souple et plus intelligente de l'énergie, la tarification dynamique de l'énergie (TDE) devient de plus en plus courante. En liant les tarifs de l'électricité aux fluctuations en temps réel, la TDE aide les
More news about: Zendure DE GmbH
May 31, 2026, 04:36 ET Zoomlion accélère le déploiement de machines agricoles au niveau mondial grâce à des produits hybrides et intelligents
intelligentes et des solutions de mécanisation spécifiques aux cultures, alignées sur la transition du secteur agricole vers des opérations plus écologiques, plus intelligentes et plus mécanisées.
More news about: Zoomlion
May 31, 2026, 01:27 ET La 4ᵉ CISCE élargit la participation internationale et sa portée mondiale
désormais 36,5 % de l'ensemble des exposants, tandis que les entreprises du Fortune Global 500 et les leaders du secteur représentent plus de 65 % des participants. Plus de 150 délégations étrangères ont confirmé leur intention de se rendre en Chine pour des réunions et des discussions d'affaires. Le nombre
More news about: China International Supply Chain Expo
May 31, 2026, 01:03 ET CATL lance le plus grand banc d'essai de stockage d'énergie au monde et fait entrer l'industrie dans l'ère de la validation en conditions réelles
d'énergie subissent des retards de connexion au réseau de plus de deux mois. Les capacités de validation étant encore largement limitées aux essais de composants et de scénarios, l'industrie a de plus en plus besoin d'un cadre de validation plus crédible au niveau des stations.Le stockage d'énergie
More news about: CATL
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Combined with Anti-PD-1 Demonstrates Durable Clinical BenefitAmong 47 enrolled treatment-naïve patients with advanced NSCLC, golidocitinib plus sintilimab following chemo-immunotherapy demonstrated encouraging and durable anti-tumor efficacy, particularly in those with high PD-L1 expression.
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
inhibitor to meet its primary endpoint in the first line treatment of NSCLC, and for the first time demonstrate that "ADC+IO" combination of sac-TMT plus pembrolizumab has the potential to achieve survival benefit as first‑line therapy for NSCLC. The publication of these findings in The Lancet
More news about: Kelun-Biotech
May 30, 2026, 14:48 ET ZPMC STS-Krane erhalten zum dritten Mal in Folge eine Auszeichnung im Rahmen des China's Manufacturing Champion Program
fortschrittlichen STS-Kranen entwickelt, die auf die unterschiedlichen Betriebsanforderungen von Terminals zugeschnitten sind, darunter der weltweit größte 3E plus STS-Kran, Niedrigprofilkrane und geräuscharme, energieeffiziente Modelle. Die automatisierten STS-Krane sind in großen Häfen auf der ganzen Welt im
More news about: ZPMC
May 30, 2026, 13:51 ET THE KILLERS DONNENT LE COUP D'ENVOI DE LA FINALE DE LA LIGUE DES CHAMPIONS DE L'UEFA, PRÉSENTÉ PAR PEPSI®
Le spectacle du coup d'envoi de la finale de l'UEFA Champions League présenté par Pepsi a eu lieu quelques minutes avant le match le plus important de la saison de football entre Arsenal FC et Paris St. Germain, avec The Killers interprétant des classiques et des hymnes
More news about: Pepsi
May 30, 2026, 11:06 ET MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
isn't text; it's warmth you can hold in your hand.International shipping of a physical toy typically costs $20–50 per parcel and takes 2–6 weeks, plus customs forms. The same care, sent as a file and printed locally? Within a day. Less than a dollar. Nearly zero carbon footprint.On MakerWorld,
More news about: Bambu Lab
May 30, 2026, 10:32 ET Gravity Game Unite (GGU) conclut avec succès l'OBT du MMORPG PC « Ragnarok Zero : Global »
existant, ainsi que par des changements apportés à la structure de croissance et à la progression générale du jeu. Le jeu offre également un environnement plus confortable grâce à l'amélioration de l'interface utilisateur et de l'interface graphique, aux fonctions de combat automatique, à l'amélioration de
More news about: Gravity Game Unite SDN. BHD.
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
collagen tile-based radiation therapy (TBRT) were more likely to survive longer without recurrence compared to the current standard of care that is surgery plus stereotactic radiation therapy (SRT) for patients with newly diagnosed operable brain metastases. The data were reported in a
More news about: GT Medical Technologies
May 30, 2026, 08:00 ET The Rosen Law Firm, P.A. Continues to Remind Investors of the Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
distribute the Settlement proceeds is fair, reasonable, and adequate; (3) the application of Lead Counsel for an award of attorneys' fees of up to one-third plus interest of the Settlement Amount, reimbursement of expenses of not more than $55,000, and awards of up to $3,500 to Lead Plaintiff and $2,500 to Plaintiff
More news about: The Rosen Law Firm, P.A.
May 30, 2026, 06:00 ET MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
isn't text; it's warmth you can hold in your hand.International shipping of a physical toy typically costs $20–50 per parcel and takes 2–6 weeks, plus customs forms. The same care, sent as a file and printed locally? Within a day. Less than a dollar. Nearly zero carbon footprint.On MakerWorld,
More news about: Bambu Lab
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
demonstrated that:Progression-free survival (PFS) showed statistically significant and clinically meaningful benefit in sac-TMT plus pembrolizumab compared with pembrolizumab alone. The median PFS assessed by blinded independent central review (BICR) was not reached (NR) vs 5.7 months
More news about: Kelun-Biotech
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
(258–345 mg) plus Capivasertib (320–400 mg) (n = 31), die einen vorläufigen Vorteil hinsichtlich des medianen progressionsfreien Überlebens (mPFS) in der Kohorte mit der empfohlenen Phase-2-Dosis (RP2D) belegen. In Kohorte 2 (n = 9) wurde die empfohlene Tagesdosis (RP2D) auf 345 mg Elacestrant plus 320 mg
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 16:30 ET AT&T to Release Second-Quarter 2026 Earnings on July 22
subscribe to email alerts.About AT&TWe help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 150 years ago to our 5G wireless and multi-gig internet offerings
More news about: AT&T
May 29, 2026, 15:16 ET TRUE GLOBAL VENTURES NOMME TAL ELYASHIV EN TANT QUE GENERAL PARTNER
Californie.« Tal apporte l'expérience de la gestion de fonds d'une société de capital-risque performante que nous recherchons chez TGV - en plus de cela, une personne qui a créé des entreprises, dirigé des institutions et investi avec conviction à travers de multiples cycles technologiques. Ses
More news about: True Global Ventures